234 related articles for article (PubMed ID: 25299513)
1. Human induced pluripotent stem cell and nanotechnology-based therapeutics.
Liu WH; Chang YL; Lo WL; Li HY; Hsiao CW; Peng CH; Chiou SH; Ma HI; Chen SJ
Cell Transplant; 2015; 24(11):2185-95. PubMed ID: 25299513
[TBL] [Abstract][Full Text] [Related]
2. Robust Differentiation of mRNA-Reprogrammed Human Induced Pluripotent Stem Cells Toward a Retinal Lineage.
Sridhar A; Ohlemacher SK; Langer KB; Meyer JS
Stem Cells Transl Med; 2016 Apr; 5(4):417-26. PubMed ID: 26933039
[TBL] [Abstract][Full Text] [Related]
3. Nanomedicine-based neuroprotective strategies in patient specific-iPSC and personalized medicine.
Jang SF; Liu WH; Song WS; Chiang KL; Ma HI; Kao CL; Chen MT
Int J Mol Sci; 2014 Mar; 15(3):3904-25. PubMed ID: 24599081
[TBL] [Abstract][Full Text] [Related]
4. Comparative study of human-induced pluripotent stem cells derived from bone marrow cells, hair keratinocytes, and skin fibroblasts.
Streckfuss-Bömeke K; Wolf F; Azizian A; Stauske M; Tiburcy M; Wagner S; Hübscher D; Dressel R; Chen S; Jende J; Wulf G; Lorenz V; Schön MP; Maier LS; Zimmermann WH; Hasenfuss G; Guan K
Eur Heart J; 2013 Sep; 34(33):2618-29. PubMed ID: 22798560
[TBL] [Abstract][Full Text] [Related]
5. Generation of clinical-grade human induced pluripotent stem cells in Xeno-free conditions.
Wang J; Hao J; Bai D; Gu Q; Han W; Wang L; Tan Y; Li X; Xue K; Han P; Liu Z; Jia Y; Wu J; Liu L; Wang L; Li W; Liu Z; Zhou Q
Stem Cell Res Ther; 2015 Nov; 6():223. PubMed ID: 26564165
[TBL] [Abstract][Full Text] [Related]
6. Evaluating the potential of poly(beta-amino ester) nanoparticles for reprogramming human fibroblasts to become induced pluripotent stem cells.
Bhise NS; Wahlin KJ; Zack DJ; Green JJ
Int J Nanomedicine; 2013; 8():4641-58. PubMed ID: 24348039
[TBL] [Abstract][Full Text] [Related]
7. Generation of Human Induced Pluripotent Stem Cells from Extraembryonic Tissues of Fetuses Affected by Monogenic Diseases.
Spitalieri P; Talarico RV; Botta A; Murdocca M; D'Apice MR; Orlandi A; Giardina E; Santoro M; Brancati F; Novelli G; Sangiuolo F
Cell Reprogram; 2015 Aug; 17(4):275-87. PubMed ID: 26474030
[TBL] [Abstract][Full Text] [Related]
8. Reprogramming of HUVECs into induced pluripotent stem cells (HiPSCs), generation and characterization of HiPSC-derived neurons and astrocytes.
Haile Y; Nakhaei-Nejad M; Boakye PA; Baker G; Smith PA; Murray AG; Giuliani F; Jahroudi N
PLoS One; 2015; 10(3):e0119617. PubMed ID: 25789622
[TBL] [Abstract][Full Text] [Related]
9. Reprogramming of bone marrow derived mesenchymal stromal cells to human induced pluripotent stem cells from pediatric patients with hematological diseases using a commercial mRNA kit.
Sfougataki I; Grafakos I; Varela I; Mitrakos A; Karagiannidou A; Tzannoudaki M; Poulou M; Mertzanian A; Roubelakis G M; Stefanaki K; Traeger-Synodinos J; Kanavakis E; Kitra V; Tzetis M; Goussetis E
Blood Cells Mol Dis; 2019 May; 76():32-39. PubMed ID: 30709626
[TBL] [Abstract][Full Text] [Related]
10. Advances in reprogramming-based study of neurologic disorders.
Nityanandam A; Baldwin KK
Stem Cells Dev; 2015 Jun; 24(11):1265-83. PubMed ID: 25749371
[TBL] [Abstract][Full Text] [Related]
11. Derivation and cardiomyocyte differentiation of induced pluripotent stem cells from heart failure patients.
Zwi-Dantsis L; Huber I; Habib M; Winterstern A; Gepstein A; Arbel G; Gepstein L
Eur Heart J; 2013 Jun; 34(21):1575-86. PubMed ID: 22621821
[TBL] [Abstract][Full Text] [Related]
12. Using human induced pluripotent stem cells to treat retinal disease.
Borooah S; Phillips MJ; Bilican B; Wright AF; Wilmut I; Chandran S; Gamm D; Dhillon B
Prog Retin Eye Res; 2013 Nov; 37():163-81. PubMed ID: 24104210
[TBL] [Abstract][Full Text] [Related]
13. Mitochondrial resetting and metabolic reprogramming in induced pluripotent stem cells and mitochondrial disease modeling.
Hsu YC; Chen CT; Wei YH
Biochim Biophys Acta; 2016 Apr; 1860(4):686-93. PubMed ID: 26779594
[TBL] [Abstract][Full Text] [Related]
14. Direct cardiac reprogramming: progress and challenges in basic biology and clinical applications.
Sadahiro T; Yamanaka S; Ieda M
Circ Res; 2015 Apr; 116(8):1378-91. PubMed ID: 25858064
[TBL] [Abstract][Full Text] [Related]
15. Induced pluripotent stem cells derived from patients carrying mitochondrial mutations exhibit altered bioenergetics and aberrant differentiation potential.
Meshrkey F; Scheulin KM; Littlejohn CM; Stabach J; Saikia B; Thorat V; Huang Y; LaFramboise T; Lesnefsky EJ; Rao RR; West FD; Iyer S
Stem Cell Res Ther; 2023 Nov; 14(1):320. PubMed ID: 37936209
[TBL] [Abstract][Full Text] [Related]
16. Human and mouse induced pluripotent stem cells are differentially reprogrammed in response to kinase inhibitors.
Hirano K; Nagata S; Yamaguchi S; Nakagawa M; Okita K; Kotera H; Ainscough J; Tada T
Stem Cells Dev; 2012 May; 21(8):1287-98. PubMed ID: 21882976
[TBL] [Abstract][Full Text] [Related]
17. Human induced pluripotent stem cells in Parkinson's disease: A novel cell source of cell therapy and disease modeling.
Li W; Chen S; Li JY
Prog Neurobiol; 2015 Nov; 134():161-77. PubMed ID: 26408505
[TBL] [Abstract][Full Text] [Related]
18. [Perspectives regarding the potential use of human induced pluripotent stem cells for the development of and research on medicinal products].
Hayakawa T; Mizuguchi H
Brain Nerve; 2012 Jan; 64(1):47-57. PubMed ID: 22223501
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of Induction: Induced Pluripotent Stem Cells (iPSCs).
Singh VK; Kumar N; Kalsan M; Saini A; Chandra R
J Stem Cells; 2015; 10(1):43-62. PubMed ID: 26665937
[TBL] [Abstract][Full Text] [Related]
20. Translational potential of hiPSCs in predictive modeling of heart development and disease.
Mansfield C; Zhao MT; Basu M
Birth Defects Res; 2022 Oct; 114(16):926-947. PubMed ID: 35261209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
